Prestige Consumer Healthcare INC

Prestige Consumer Healthcare Inc. announced the retirement of Senior Vice President, Operations, Jeffrey Zerillo, effective August 14, 2026.

Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, exceeding revenue and earnings expectations, and raised its full-year financial outlook following the successful closure of two key acquisitions.

Prestige Consumer Healthcare Inc. announced the issuance of $400 million in 6.250% senior notes due 2034 through its subsidiary, Prestige Brands, Inc.

Prestige Consumer Healthcare Inc. files an amended 8-K to clarify financial statements related to its acquisition of the Breathe Right and other brands from Foundation Consumer Brands, LLC.

Prestige Consumer Healthcare Inc. has closed its acquisition of LaCorium Health, priced a $400 million senior notes offering, and will report Q1 FY2027 earnings on August 6, 2026.

Prestige Consumer Healthcare Inc. files an 8-K/A to provide financial statements and pro forma information related to its acquisition of the OTC Wellness Business from Foundation Consumer Brands, LLC.

Prestige Consumer Healthcare Inc. reported a 6.5% increase in total revenues for the three months ended June 30, 2026, driven by the acquisition of the OTC Wellness Business.

Prestige Consumer Healthcare reports a decline in Q3 net income and revenues, impacted by supply chain issues and a significant supplier loan write-off, despite strategic acquisitions.

Prestige Consumer Healthcare reported a decline in Q2 net income and revenue, while simultaneously announcing the acquisition of Pillar5 Pharma Inc. for $150 million.

Prestige Consumer Healthcare Inc. reported a 6.6% decline in total revenues for the first quarter of fiscal 2026, primarily due to supply constraints in its North American Eye & Ear Care segment, despite improved gross profit margins and strong operating cash flow.

Prestige Consumer Healthcare's Q3 2025 results show a slight revenue increase and continued efforts to manage economic uncertainties and debt.

Prestige Consumer Healthcare experienced a minor decrease in revenue for the second quarter of fiscal year 2025, while maintaining profitability.

Prestige Consumer Healthcare Inc. announced its fiscal year 2026 results, showing a decrease in total revenues and gross profit, impacted by supply chain challenges and acquisition costs.

Prestige Consumer Healthcare's fiscal year 2025 results show a slight revenue increase amid economic volatility, with strategic focus on brand growth and efficient operations.

Prestige Consumer Healthcare Inc. released its annual report for the fiscal year ended March 31, 2024, showing a slight decrease in total segment revenues and a modest increase in gross profit margin.

John E Byom, a Director of Prestige Consumer Healthcare Inc., received 2,981 shares of common stock on August 4, 2026.

Christine Sacco, CFO & COO of Prestige Consumer Healthcare Inc., reported a sale of 1,091 shares of common stock on May 2, 2026.

Jeffrey Zerillo, Senior VP Operations at Prestige Consumer Healthcare Inc., reported a sale of 351 shares of common stock on May 11, 2026.

Prestige Consumer Healthcare Inc. reports insider transactions involving Senior VP Operations, Jeffrey Zerillo, with the acquisition and disposition of company stock.

Christine Sacco, CFO & COO of Prestige Consumer Healthcare Inc., reported a sale of 991 shares of common stock on May 7, 2026.

Ronald M. Lombardi, CEO and Director of Prestige Consumer Healthcare Inc., reported a transaction involving the acquisition of 2,543 shares of common stock.

Prestige Consumer Healthcare Inc. has released its 2026 Proxy Statement, detailing upcoming annual meeting agenda items, director nominations, executive compensation, and corporate governance.

Prestige Consumer Healthcare Inc. reported record revenues, adjusted earnings per share, and strong free cash flow for fiscal year 2025, demonstrating consistent growth and strategic execution.

Prestige Consumer Healthcare Inc. is holding its 2024 Annual Meeting of Stockholders on August 6, 2024, to vote on key proposals including the election of directors, ratification of the independent auditor, executive compensation, and an amendment to the company's certificate of incorporation.

Ariel Investments, LLC has increased its beneficial ownership of Prestige Consumer Healthcare Inc. common stock to 10.3%, acquiring 4,868,711 shares.

Vanguard Capital Management has reported beneficial ownership of 2,454,974 shares, representing 5.18% of the outstanding common stock of Prestige Consumer Healthcare Inc.

Vanguard Portfolio Management has reported beneficial ownership of 5.97% of Prestige Consumer Healthcare Inc.'s common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G for Prestige Consumer Healthcare Inc., reporting 0% beneficial ownership following an internal realignment.

Ariel Investments, LLC has disclosed an 8.5% beneficial ownership stake in Prestige Consumer Healthcare Inc., holding over 4.1 million shares.

Ariel Investments, LLC has reported a 7.3% beneficial ownership stake in Prestige Consumer Healthcare I, holding 3,594,959 shares of common stock.